SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Evidence Supporting Liver Targeting of Tenofovir Exalidex (TXL)- Dr. R. FosterView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017RNA Interference Screen Identified Farnesoid X Receptor (FXR) as a Host Dependency Factor for HBV Establishment in Primary Human Hepatocytes- Dr. S. GhoshView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Aramchol for NASH and beyond: From scientific rationale to clinical development- Carol BrosgartView Slideset
MHEManal Hamdy El-SayedMD, PhDSlidesetViral Hepatitis and Liver DiseaseHEP DART 2017The Effectiveness of Treatment for Chronic Hepatitis C (and Hepatitis B) in Pediatric Populations- Manal El-Sayed, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Liver Directed Acetyl-CoA Carboxylase Inhibitor GS-0976 For NASH (not available)- Adrian RayView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Lessons learned towards a Vaccine and Functional Cure for HIV (not available)- Mario StevensonView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Seroclearance of HBsAg in Chronic Hepatitis B Virus Patients on Lamivudine, Tenofovir or Entecavir Therapy: A 10 Year Experience- Dr. S. OnoView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Hepatitis B virus splice variants are associated with and predictive of Liver cancer- Dr. P. RevillView Slideset
ACAndrea CoxMDSlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Update on Prophylactic HCV Vaccine Development- Andrea Cox, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017The Re-vival of Bile Acid Based Therapeutics for Children and Adults- Saul KarpenView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017High Efficacy and Safety of the combination HCV Regimen Grazoprevir and Elbasvir for 8 Weeks in Treatment-Naive, non-severe fibrosis HCV GT1b-Infected Patients: Interim Results of the STREAGER study- Dr. A. AbergelView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Sustained SVR 2 years after HCV treatment with simeprevir, daclatasvir and sofosbuvir in patients with portal hypertension or decompensated liver disease (not available)- Dr. E. LawitzView Slideset
